New Progress in the Treatment of Diffuse Midline Glioma with H3K27M Alteration

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Feb 5

PMID 38312649

Authors

Zhi Yang

Liang Sun

Haibin Chen

Caixing Sun

Liang Xia

Affiliations

Soon will be listed here.

Abstract

Diffuse midline glioma with H3K27 M alteration is a primary malignant tumor located along the linear structure of the brain, predominantly manifesting in children and adolescents. The mortality rate is exceptionally high, with a mere 1 % 5-year survival rate for newly diagnosed patients. Beyond conventional surgery, radiotherapy, and chemotherapy, novel approaches are imperative to enhance patient prognosis. This article comprehensively reviews current innovative treatment modalities and provides updates on the latest research advancements in preclinical studies and clinical trials focusing on H3K27M-altered diffuse midline glioma. The goal is to contribute positively to clinical treatment strategies.

Citing Articles

A narrative review of epigenetic marker in H3K27ac and its emerging potential as a therapeutic target in cancer.

Zhu M, Lu X, Wang D, Ma J, Wang Y, Wang R Epigenomics. 2025; 17(4):263-279.

PMID: 39981972 PMC: 11853624. DOI: 10.1080/17501911.2025.2460900.

Latest Advancements in the Management of H3K27M-Mutant Diffuse Intrinsic Pontine Glioma: A Narrative Review.

Lo Greco M, Marano G, La Rocca M, Acquaviva G, Milazzotto R, Liardo R Cancers (Basel). 2025; 17(3).

PMID: 39941789 PMC: 11815860. DOI: 10.3390/cancers17030420.

Extracellular Histones Profiles of Pediatric H3K27-Altered Diffuse Midline Glioma.

Buzova D, Petrilli L, Frohlich J, Tsoneva D, Bianco S, Braghini M Mol Diagn Ther. 2024; 29(1):129-141.

PMID: 39514166 DOI: 10.1007/s40291-024-00754-6.

Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors.

Holtermann A, Gislon M, Angele M, Subklewe M, von Bergwelt-Baildon M, Lauber K BioDrugs. 2024; 38(5):611-637.

PMID: 39080180 PMC: 11358237. DOI: 10.1007/s40259-024-00669-y.

References

Schneider S, Potthast S, Komminoth P, Schwegler G, Bohm S . PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis. Case Rep Oncol. 2017; 10(2):473-478. PMC: 5471763. DOI: 10.1159/000477162. View

Perez-Callejo D, Romero A, Provencio M, Torrente M . Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. Transl Lung Cancer Res. 2016; 5(5):455-465. PMC: 5099509. DOI: 10.21037/tlcr.2016.10.07. View

Cockle J, Bruning-Richardson A, Scott K, Thompson J, Kottke T, Morrison E . Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion. Mol Ther Oncolytics. 2017; 5:75-86. PMC: 5435599. DOI: 10.1016/j.omto.2017.04.002. View

Cantor E, Wierzbicki K, Tarapore R, Ravi K, Thomas C, Cartaxo R . Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. Neuro Oncol. 2022; 24(8):1366-1374. PMC: 9340643. DOI: 10.1093/neuonc/noac030. View

Cohen K, Jabado N, Grill J . Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?. Neuro Oncol. 2017; 19(8):1025-1034. PMC: 5570259. DOI: 10.1093/neuonc/nox021. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Gargett T, Yu W, Dotti G, Yvon E, Christo S, Hayball J . GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. Mol Ther. 2016; 24(6):1135-1149. PMC: 4923328. DOI: 10.1038/mt.2016.63. View

Curran K, Pegram H, Brentjens R . Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med. 2012; 14(6):405-15. PMC: 4697438. DOI: 10.1002/jgm.2604. View

Curran C, Kopp J . PD-1 immunobiology in glomerulonephritis and renal cell carcinoma. BMC Nephrol. 2021; 22(1):80. PMC: 7936245. DOI: 10.1186/s12882-021-02257-6. View

10.

Ladomersky E, Zhai L, Lenzen A, Lauing K, Qian J, Scholtens D . IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clin Cancer Res. 2018; 24(11):2559-2573. PMC: 5984675. DOI: 10.1158/1078-0432.CCR-17-3573. View

11.

Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J . Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022; 28(8):1630-1639. PMC: 9388376. DOI: 10.1038/s41591-022-01897-x. View

12.

Berraondo P, Sanmamed M, Ochoa M, Etxeberria I, Aznar M, Perez-Gracia J . Cytokines in clinical cancer immunotherapy. Br J Cancer. 2018; 120(1):6-15. PMC: 6325155. DOI: 10.1038/s41416-018-0328-y. View

13.

Kline C, Liu S, Duriseti S, Banerjee A, Nicolaides T, Raber S . Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. J Neurooncol. 2018; 140(3):629-638. DOI: 10.1007/s11060-018-2991-5. View

14.

Sanchez-Perez L, Kottke T, Daniels G, Diaz R, Thompson J, Pulido J . Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. J Immunol. 2006; 177(6):4168-77. DOI: 10.4049/jimmunol.177.6.4168. View

15.

Ma R, Li Z, Chiocca E, Caligiuri M, Yu J . The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2022; 9(2):122-139. PMC: 9877109. DOI: 10.1016/j.trecan.2022.10.003. View

16.

Kirson E, Schneiderman R, Dbaly V, Tovarys F, Vymazal J, Itzhaki A . Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys. 2009; 9:1. PMC: 2647898. DOI: 10.1186/1756-6649-9-1. View

17.

Dawson S, Tsui D, Murtaza M, Biggs H, Rueda O, Chin S . Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368(13):1199-209. DOI: 10.1056/NEJMoa1213261. View

18.

Lin G, Wilson K, Ceribelli M, Stanton B, Woo P, Kreimer S . Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci Transl Med. 2019; 11(519). PMC: 7132630. DOI: 10.1126/scitranslmed.aaw0064. View

19.

Leszczynska K, Jayaprakash C, Kaminska B, Mieczkowski J . Emerging Advances in Combinatorial Treatments of Epigenetically Altered Pediatric High-Grade H3K27M Gliomas. Front Genet. 2021; 12:742561. PMC: 8503186. DOI: 10.3389/fgene.2021.742561. View

20.

Majzner R, Mackall C . Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov. 2018; 8(10):1219-1226. DOI: 10.1158/2159-8290.CD-18-0442. View